# Drug of interest
My drug of interest is sulfadoxine.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. NAT2 (z: 6.84)
2. G6PD (z: 2.66)
3. CYP2C19 (z: 1.65)
4. NAT1 (z: 1.48)
5. ABCB1 (z: 1.48)
6. ABCG2 (z: 1.06)
7. CYP2C9 (z: 0.89)
8. IKBKG (z: 0.65)
9. HLA-B (z: 0.62)
10. CYP2A6 (z: 0.46)
11. CYP2B6 (z: 0.38)
12. HLA-C (z: 0.36)
13. CYP2E1 (z: 0.33)
14. CYP2D7 (z: 0.31)
15. MT-RNR1 (z: 0.31)
16. HLA-G (z: 0.3)
17. CERS6 (z: 0.3)
18. ATAT1 (z: 0.27)
19. ABCB4 (z: 0.27)
20. HLA-A (z: 0.26)
21. CYP2A7 (z: 0.23)
22. ADORA2A-AS1 (z: 0.23)
23. HCP5 (z: 0.22)
24. CYP2F1 (z: 0.21)
25. HLA-E (z: 0.21)
26. CHAT (z: 0.19)
27. CYP2S1 (z: 0.19)
28. HLA-DRB1 (z: 0.16)
29. HLA-DQB1 (z: 0.16)
30. CYP2C18 (z: 0.16)
31. CYP2A13 (z: 0.15)
32. C5orf56 (z: 0.15)
33. CYP2J2 (z: 0.15)
34. NR1I2 (z: 0.15)
35. ACE (z: 0.14)
36. ABCB11 (z: 0.13)
37. HLA-DPB1 (z: 0.13)
38. MBOAT1 (z: 0.13)
39. CPT1A (z: 0.13)
40. HLA-DPA1 (z: 0.12)
41. SLC22A14 (z: 0.11)
42. CYP2D6 (z: 0.11)
43. GCLC (z: 0.11)
44. HLA-DRA (z: 0.1)
45. HLA-DRB5 (z: 0.09)
46. HLA-DRB3 (z: 0.09)
47. CYB5R3 (z: 0.09)
48. AGPAT2 (z: 0.09)
49. GSTA3 (z: 0.09)
50. F13A1 (z: 0.08)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**sulfadoxine**: Sulfadoxine, an antimalarial drug, interacts pharmacodynamically with human genetics primarily through considerations of glucose-6-phosphate dehydrogenase (G6PD) deficiency, which can increase risks of hemolysis when patients with this genetic condition are treated with sulfadoxine. Additionally, while not thoroughly documented, interactions might exist with the cytochrome P450 enzyme system, potentially affecting drug metabolization in combination therapies like Fansidar, although this is more speculative and relevant to the pyrimethamine component of the drug.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**NAT2**: The NAT2 gene encodes an enzyme crucial for the metabolism of various drugs through N-acetylation, influencing their pharmacokinetics and toxicity. Variants in NAT2 affect the metabolism of drugs like isoniazid, hydralazine, procainamide, sulfamethoxazole, and pyrazinamide, leading to differences in acetylator status (rapid, intermediate, slow) among individuals, which impacts drug plasma levels, exposure duration, and risk of adverse effects such as increased toxicity and drug-induced lupus.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**NAT1**: The NAT1 enzyme, which catalyzes the acetylation of various substrates, affects the metabolism and efficacy of several drugs including cotinine, thioguanine, and mesalazine. Variations in NAT1 activity influence the effectiveness and side effect profiles of these drugs by altering their metabolic pathways, which is critical for determining optimal dosages and therapeutic strategies tailored to individual genetic profiles.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**IKBKG**: The interactions between the IKBKG gene and antimalarial drugs such as pyrimethamine, artesunate, sulfadoxine, and primaquine are largely pharmacodynamic, affecting the NF-kappaB signaling pathway and consequently impacting the immune response needed to combat malaria. Mutations in the IKBKG gene can modify the immune system's response, thus potentially influencing the efficacy of these drugs in individuals with such genetic variations.

**HLA-B**: The HLA-B gene plays a crucial role in drug hypersensitivity reactions through allele-specific interactions, such as the HLA-B*57:01 allele causing severe reactions to abacavir and the HLA-B*15:02 allele being associated with severe adverse reactions to carbamazepine. These interactions, which involve the immune system's response to drug-modified peptides or the drug itself presented by the HLA-B protein, emphasize the importance of genetic testing in precision medicine to tailor drug therapy and minimize adverse reactions based on individual genetic profiles.

**CYP2A6**: CYP2A6, an enzyme from the cytochrome P450 superfamily, influences the metabolism of various drugs, impacting their efficacy and toxicity due to genetic variations. It plays a critical role in metabolizing smoking cessation aids like nicotine, cancer treatments such as cyclophosphamide and tegafur, HIV treatment efavirenz, and the glaucoma drug pilocarpine, necessitating dosage adjustments or changes in drug choices to optimize outcomes and minimize side effects.

**CYP2B6**: CYP2B6 plays a pivotal role in the metabolism of several drugs, including efavirenz, nevirapine, methadone, bupropion, cyclophosphamide, and ifosfamide, where genetic polymorphisms can significantly influence drug efficacy and safety by altering pharmacokinetic profiles. Genetic variations in CYP2B6 affect the enzyme activity, leading to differences in drug plasma concentrations, therapeutic effects, and potential adverse reactions in individuals, underscoring its importance in personalized medicine.

**HLA-C**: HLA-C plays a crucial role in drug hypersensitivity reactions, primarily through immune response mechanisms influenced by its polymorphic nature. The presence of the HLA-C*06:02 allele, for example, is strongly associated with hypersensitivity to abacavir, used in HIV treatment, necessitating genetic screening to prevent severe reactions. Other drugs such as carbamazepine, allopurinol, clozapine, and phenytoin also show interactions with various HLA alleles that might contribute to adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.

**CYP2E1**: The gene CYP2E1 significantly impacts the metabolism of various drugs; for instance, in the case of acetaminophen and isoniazid, variations in CYP2E1 activity can lead to differences in the rate at which these drugs are metabolized, thereby affecting their efficacy, toxicity, and risk of adverse effects such as hepatotoxicity. Additionally, CYP2E1 metabolizes other substances like caffeine, theophylline, nicotine, and some procarcinogens, indicating that genetic variations could influence both therapeutic outcomes and disease risk through pharmacokinetic and possibly pharmacodynamic interactions.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**MT-RNR1**: The MT-RNR1 gene mutation m.1555A>G heightens susceptibility to ototoxic effects from aminoglycoside antibiotics such as gentamicin and tobramycin due to increased sensitivity of the mitochondrial ribosome, leading to impaired protein synthesis in cochlear cells and increasing the risk of irreversible hearing loss. The interaction between MT-RNR1 and aminoglycosides is pharmacodynamic as it influences the drug's action on the mitochondrial ribosome, rather than affecting the drug's metabolism or disposition.

**HLA-G**: HLA-G's potential pharmacodynamic interactions with drugs like fluorouracil, irinotecan, methotrexate, and capecitabine, primarily used in chemotherapy, relate to its role in modulating immune responses which could influence the immune system's ability to recognize and destroy tumor cells. These interactions likely result from HLA-G enhancing immune evasion capabilities in cancer cells, thereby potentially modifying the therapeutic efficacy of the mentioned drugs.

**CERS6**: Drugs that modulate sphingolipid metabolism, specifically ceramides, may have their efficacy and safety profiles altered by the functional status of the CERS6 gene in diseases like cancer, diabetes, and neurodegenerative disorders. This interaction is primarily pharmacodynamic, affecting how drugs influence disease pathways mediated by ceramides, rather than altering the drug metabolism directly.

**ATAT1**: Drugs like carboplatin and gemcitabine, used in cancer treatment, indirectly affect the function of the ATAT1 gene, which is critical for the stability of microtubules, by disrupting microtubule dynamics and DNA replication mechanisms. This indirect interaction may impact the efficacy of these drugs and lead to variations in patient responses based on differences in ATAT1 expression levels or genetic variants.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**HLA-A**: The HLA-A gene is crucial in pharmacogenetic interactions due to its role in immune-mediated hypersensitivity reactions to certain drugs. For instance, the HLA-A*31:01 allele increases the risk of severe skin reactions to carbamazepine, while the HLA-A*02:01 allele is linked to severe adverse reactions to allopurinol, both through mechanisms involving the immune system's response to these drugs or their metabolites. Other drugs such as abacavir, phenytoin, and flucloxacillin among others are also implicated in similar immune responses based on the HLA-A gene variations, affecting drug pharmacodynamics rather than pharmacokinetics.

**CYP2A7**: CYP2A7, a lesser-known member of the cytochrome P450 family, does not have well-established pharmacogenetic interactions with drugs like mercaptopurine, although it might theoretically affect mercaptopurine's metabolism similarly to its related isoform, CYP2A6. The interaction and impact of CYP2A7 on the metabolism of mercaptopurine are speculative and require further evidence, as mercaptopurine is primarily metabolized through other pathways involving TPMT and XO.

**ADORA2A-AS1**: The gene ADORA2A-AS1, encoding the antisense RNA of ADORA2A, indirectly influences the effectiveness of drugs targeting the adenosine A2a receptor by modulating the receptor's expression. Among these, caffeine, an antagonist of the A2a receptor, can have altered stimulatory effects due to changes in ADORA2A expression mediated by ADORA2A-AS1, while the connection between ADORA2A-AS1 and methotrexate's effects is less certain and speculative.

**HCP5**: HCP5 plays a crucial role in pharmacogenetics, specifically interacting with abacavir, a drug used in HIV treatment. The hypersensitivity to abacavir is linked to the HCP5-related rs2395029 polymorphism, which affects the expression of the HLA-B*5701 allele, necessitating genetic testing before prescribing the drug to avoid severe adverse reactions. While there are potential interactions with other immune-modulating drugs, such as flucloxacillin and gemcitabine, these are not as clearly defined as the interaction with abacavir.

**CYP2F1**: CYP2F1, involved mainly in metabolizing inhaled environmental pollutants like naphthalene, has limited direct interaction with common drugs but plays a role in the metabolism of certain pharmaceuticals such as imatinib due to shared metabolic pathways or competitive inhibition. Although CYP2F1 does not typically directly influence imatinib's metabolism, its interaction with similar chemical structures could alter the drug's efficacy or toxicity in individuals with specific gene variants.

**HLA-E**: The gene HLA-E, which plays a significant role in immune system regulation, may interact pharmacodynamically with methotrexate, a drug used for autoimmune diseases and cancer. This interaction likely occurs as methotrexate modulates immune responses that are under the control of HLA-E, affecting drug efficacy and potential adverse effects rather than affecting the drug's absorption, distribution, metabolism, or excretion.

**CHAT**: The gene CHAT, critical for synthesizing acetylcholine, interacts with acetylcholinesterase inhibitors such as rivastigmine, donepezil, and galantamine, used in Alzheimer's disease management, by affecting their pharmacodynamics as these drugs aim to increase acetylcholine levels by preventing its breakdown. Variations in CHAT expression among individuals can amplify or modify the effects of these medications, while olanzapine, though primarily an antipsychotic, may also interact indirectly through CHAT due to its broad receptor influence on cognitive and neuromuscular systems.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**HLA-DRB1**: The HLA-DRB1 gene, through its various alleles, significantly influences the pharmacogenetic interactions that affect the efficacy and safety of medications, causing immune-mediated hypersensitivity reactions. For instance, the HLA-DRB1*15:01 allele is linked to abacavir hypersensitivity in HIV treatment, while HLA-DRB1*07:01 is associated with hepatic injuries from ximelagatran, highlighting the importance of understanding a patient's HLA-DRB1 allele status to optimize and personalize treatment strategies.

**HLA-DQB1**: HLA-DQB1 gene variants significantly impact drug hypersensitivity reactions, particularly for drugs like abacavir, allopurinol, nevirapine, lamotrigine, and carbamazepine, which can cause severe reactions such as Steven-Johnson syndrome and toxic epidermal necrolysis in genetically predisposed individuals. These interactions emphasize the role of HLA-DQB1 in pharmacodynamics, affecting drug safety and efficacy rather than drug metabolism.

**CYP2C18**: CYP2C18 plays a modest role in the metabolism of drugs like warfarin, escitalopram, and clozapine, mainly affecting their clearance or efficacy to a lesser extent than more prominent CYP enzymes. Genetic variations in CYP2C18 could influence the pharmacodynamics of drugs such as clopidogrel and acenocoumarol, rather than their pharmacokinetic profiles, indicating a potential need for personalized medicine considerations despite the enzyme's relative minor role.

**CYP2A13**: CYP2A13, a cytochrome P450 enzyme primarily found in the respiratory tract, plays a significant role in activating procarcinogens in tobacco smoke, such as nitrosamines, impacting lung cancer risk among smokers. Although it does not metabolize nicotine directly, CYP2A13 affects the activation of other smoke components that interact with nicotine's pathway, potentially influencing nicotine addiction and cancer risks, with genetic variations in CYP2A13 altering susceptibility to these effects.

**C5orf56**: C5orf56, a gene implicated in inflammatory and autoimmune processes, might affect the response to drugs such as hydrochlorothiazide through pharmacodynamic interactions relating to its role in inflammation, rather than through alterations in drug metabolism. These potential interactions, which are yet speculative, suggest that C5orf56 could modulate the effects of hydrochlorothiazide on blood pressure and cardiovascular health via immune modulation or inflammation.

**CYP2J2**: CYP2J2, primarily involved in metabolizing polyunsaturated fatty acids affecting cardiovascular physiology, does not have well-documented direct pharmacokinetic interactions with drugs like mycophenolate mofetil and tacrolimus. However, its role in modulating vascular tone and inflammation could potentially influence the pharmacodynamics of these immunosuppressive drugs used in organ transplantation and autoimmune diseases, despite the lack of a direct metabolic pathway involving CYP2J2.

**NR1I2**: NR1I2, or pregnane X receptor (PXR), regulates genes encoding drug-metabolizing enzymes and transport systems like CYP3A4 and MDR1, influencing the pharmacokinetics of various drugs. Activators of NR1I2 such as rifampin and carbamazepine can increase the metabolism and decrease the efficacy of drugs like sirolimus and rosuvastatin by upregulating CYP3A4, while inhibitors can slow metabolism, increasing toxicity risk.

**ACE**: Variability in the ACE gene, such as the insertion (I) or deletion (D) polymorphism, impacts the effectiveness and side effects of ACE inhibitors including lisinopril, enalapril, and others by altering the enzyme that regulates blood pressure and vasoconstriction. Although not directly interacting with the ACE enzyme, drugs like hydrochlorothiazide, losartan, and amlodipine, along with others such as spironolactone and atenolol, might still exhibit variable responses due to changes in the renin-angiotensin system mediated by the ACE gene, highlighting its central role in cardiovascular pharmacotherapy.

**ABCB11**: The gene ABCB11, which codes for the bile salt export pump (BSEP), significantly influences the pharmacokinetics of several drugs, including rosuvastatin, ribavirin, odevixibat, and glyburide, by affecting their hepatic uptake, biliary excretion, or both. Variants in ABCB11 may alter the efficacy and toxicity of these medications, highlighting its importance in personalized drug therapy.

**HLA-DPB1**: HLA-DPB1, a gene expressed in antigen-presenting cells, primarily affects drug hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) through immune modulation, particularly in pharmacodynamic interactions. For example, its specific alleles may increase the risk of agranulocytosis in patients treated with the antipsychotic drug clozapine, while there is no confirmed pharmacogenetic interaction between HLA-DPB1 and aspirin.

**MBOAT1**: MBOAT1, crucial in ghrelin acylation and therefore appetite stimulation and energy balance, could be interacted with by drugs targeting metabolic or appetite control pathways, either influencing its expression or enzymatic activity. Particularly, this interaction might involve medications influencing ghrelin or those affecting similar metabolic processes, such as weight management or anti-obesity drugs, and potentially extends to drugs targeting lipid enzymes, affecting MBOAT1's function or efficiency.

**CPT1A**: The gene CPT1A, critical in mitochondrial fatty acid oxidation, affects the efficacy and toxicity of anticancer drugs like doxorubicin, vincristine, and cyclophosphamide through its role in cellular energetics and mitochondrial functions. Although direct pharmacokinetic interactions are not established, CPT1A's influence on cell survival, drug resistance, and apoptosis can crucially impact the pharmacodynamics of these chemotherapeutic agents, thereby affecting treatment outcomes.

**HLA-DPA1**: HLA-DPA1 influences immune responses and plays a significant role in hypersensitivity to drugs such as abacavir, used in HIV treatment, due to its function in antigen presentation and subsequent immune activation. While it doesn’t affect the metabolism or elimination of aspirin, it may impact the immune-mediated adverse reactions to aspirin, suggesting a potential pharmacodynamic interaction through modulation of inflammatory pathways.

**SLC22A14**: SLC22A14, a gene involved in the transport of organic cations and primarily expressed in the testis, lacks established pharmacogenetic interactions with any drugs due to limited research. Currently, there are no known effects from this gene on drug absorption, metabolism, excretion, or pharmacodynamics, making its role in drug response purely speculative at this time.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**GCLC**: The GCLC gene, responsible for glutathione synthesis, interacts pharmacogenetically with drugs like cisplatin, doxorubicin, and sulfamethoxazole, which induce oxidative stress. Variations in the GCLC gene can influence the efficacy and side effect profile of these drugs, as they rely on glutathione for detoxification and mitigating cellular damage. This interaction underscores the importance of considering genetic differences in managing therapies that involve oxidative stress mechanisms.

**HLA-DRA**: The HLA-DRA gene, though not directly interacting with drugs through pharmacokinetic pathways, plays an indirect role in pharmacodynamics due to its involvement in the immune system. It is implicated in the immune-mediated drug reactions, such as hypersensitivities to antibiotics like amoxicillin, flucloxacillin, and clavulanate, possibly by affecting how drug-related antigens are presented to the immune system by antigen-presenting cells, thereby influencing the likelihood or severity of allergic reactions.

**HLA-DRB5**: HLA-DRB5 affects the pharmacogenetics of clavulanate, amoxicillin, and clozapine by modulating immune responses rather than altering drug metabolism or transport. In the cases of clavulanate and amoxicillin, this can lead to hypersensitivity reactions, while for clozapine, it can influence the risk of agranulocytosis, all due to variations in HLA-DRB5 that affect the immune system's reaction to these drugs.

**HLA-DRB3**: HLA-DRB3, a gene involved in immune system response, interacts with drugs not by being directly targeted but by influencing how the immune system interacts with these drugs, thus modulating their effects and potentially leading to drug hypersensitivity reactions. For example, variations in HLA-DRB3 are linked to different responses and adverse reactions to drugs like clozapine, where a connection is suggested between HLA alleles and clozapine-induced agranulocytosis, highlighting the gene's role in drug efficacy and safety.

**CYB5R3**: The CYB5R3 gene is involved in drug metabolism, catalyzing the reduction of methemoglobin back to hemoglobin, which is crucial for the metabolism of drugs like Aniline Dyes, Benzocaine, Dapsone, and Primaquine. These drugs can cause Methemoglobinemia particularly when CYB5R3 function is compromised due to genetic mutations or if the enzyme’s metabolic capacity is overwhelmed, leading to impaired oxygen transport and delivery in affected individuals.

**AGPAT2**: Although AGPAT2 does not have direct pharmacogenetic interactions with drugs, its role in lipid metabolism and adipocyte function suggests that drugs targeting lipid disorders or insulin resistance, such as statins, metformin, and pioglitazone, might have varying efficacy due to indirect influences on AGPAT2-related pathways. This gene's involvement in broader metabolic conditions indirectly affects how these drugs interact within the body, rather than through direct drug-gene interactions.

**GSTA3**: GSTA3, part of the glutathione S-transferase family, plays a critical role in detoxifying xenobiotics and drugs, particularly by enhancing the solubility and excretion of agents susceptible to conjugation with glutathione such as certain antineoplastic agents. This enzymatic activity could reduce the effectiveness of drugs like alkylating agents used in chemotherapy by accelerating their detoxification, impacting therapeutic outcomes.

**F13A1**: The pharmacogenetic profile of F13A1 gene affects both the effectiveness and safety of Factor XIII concentrates used in treating Factor XIII deficiency by determining the biological availability and action of these treatments. While drugs like clopidogrel and aspirin, which interfere with platelet function and clot formation, do not directly interact pharmacokinetically with F13A1, their use in patients with clotting disorders associated with F13A1 mutations can affect the hemostatic balance due to F13A1's central role in the clotting cascade.
